Titre : Syndromes parkinsoniens

Syndromes parkinsoniens : Questions médicales fréquentes

Termes MeSH sélectionnés :

Double-Blind Method
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndromes parkinsoniens : Questions médicales les plus fréquentes", "headline": "Syndromes parkinsoniens : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndromes parkinsoniens : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-25", "dateModified": "2025-04-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndromes parkinsoniens" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles de la motricité", "url": "https://questionsmedicales.fr/mesh/D009069", "about": { "@type": "MedicalCondition", "name": "Troubles de la motricité", "code": { "@type": "MedicalCode", "code": "D009069", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.662" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Syndrome parkinsonien secondaire", "alternateName": "Parkinson Disease, Secondary", "url": "https://questionsmedicales.fr/mesh/D010302", "about": { "@type": "MedicalCondition", "name": "Syndrome parkinsonien secondaire", "code": { "@type": "MedicalCode", "code": "D010302", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.662.600.700" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Maladie de Parkinson post-encéphalitique", "alternateName": "Parkinson Disease, Postencephalitic", "url": "https://questionsmedicales.fr/mesh/D010301", "about": { "@type": "MedicalCondition", "name": "Maladie de Parkinson post-encéphalitique", "code": { "@type": "MedicalCode", "code": "D010301", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.662.600.700.500" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Syndromes parkinsoniens", "alternateName": "Parkinsonian Disorders", "code": { "@type": "MedicalCode", "code": "D020734", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sara Hall", "url": "https://questionsmedicales.fr/author/Sara%20Hall", "affiliation": { "@type": "Organization", "name": "Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden." } }, { "@type": "Person", "name": "Shorena Janelidze", "url": "https://questionsmedicales.fr/author/Shorena%20Janelidze", "affiliation": { "@type": "Organization", "name": "Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden." } }, { "@type": "Person", "name": "Oskar Hansson", "url": "https://questionsmedicales.fr/author/Oskar%20Hansson", "affiliation": { "@type": "Organization", "name": "Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden." } }, { "@type": "Person", "name": "Hash Brown Taha", "url": "https://questionsmedicales.fr/author/Hash%20Brown%20Taha", "affiliation": { "@type": "Organization", "name": "Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA." } }, { "@type": "Person", "name": "Carlo Colosimo", "url": "https://questionsmedicales.fr/author/Carlo%20Colosimo", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Santa Maria University Hospital, Terni, Italy. Electronic address: carlo.colosimo@uniroma1.it." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Evaluating the effectiveness of stromal-vascular fraction (SVF) cells along with subcision method in the treatment of acne scars: A double-blind randomized controlled clinical trial study.", "datePublished": "2022-09-26", "url": "https://questionsmedicales.fr/article/36086927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocd.15375" } }, { "@type": "ScholarlyArticle", "name": "ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.", "datePublished": "2022-12-20", "url": "https://questionsmedicales.fr/article/36600424", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-067251" } }, { "@type": "ScholarlyArticle", "name": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.", "datePublished": "2022-05-23", "url": "https://questionsmedicales.fr/article/35617986", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2213-2600(22)00088-1" } }, { "@type": "ScholarlyArticle", "name": "Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.", "datePublished": "2024-08-14", "url": "https://questionsmedicales.fr/article/39161682", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/DDDT.S472651" } }, { "@type": "ScholarlyArticle", "name": "Efficacy of Liposomal Melatonin in sleep EEG in Childhood: A Double Blind Case Control Study.", "datePublished": "2022-12-29", "url": "https://questionsmedicales.fr/article/36612875", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph20010552" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Maladies du système nerveux central", "item": "https://questionsmedicales.fr/mesh/D002493" }, { "@type": "ListItem", "position": 4, "name": "Troubles de la motricité", "item": "https://questionsmedicales.fr/mesh/D009069" }, { "@type": "ListItem", "position": 5, "name": "Syndromes parkinsoniens", "item": "https://questionsmedicales.fr/mesh/D020734" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndromes parkinsoniens - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndromes parkinsoniens", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndromes parkinsoniens", "description": "Comment diagnostiquer un syndrome parkinsonien ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les critères de diagnostic ?\nPeut-on confondre avec d'autres maladies ?\nQuel rôle joue l'historique médical ?", "url": "https://questionsmedicales.fr/mesh/D020734?mesh_terms=Double-Blind+Method&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndromes parkinsoniens", "description": "Quels sont les symptômes moteurs principaux ?\nQuels symptômes non moteurs sont fréquents ?\nComment évoluent les symptômes ?\nY a-t-il des symptômes précoces ?\nLes symptômes affectent-ils la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D020734?mesh_terms=Double-Blind+Method&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndromes parkinsoniens", "description": "Peut-on prévenir les syndromes parkinsoniens ?\nQuel rôle joue l'exercice physique ?\nL'alimentation influence-t-elle le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLe stress a-t-il un impact ?", "url": "https://questionsmedicales.fr/mesh/D020734?mesh_terms=Double-Blind+Method&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndromes parkinsoniens", "description": "Quels sont les traitements médicamenteux ?\nLa chirurgie est-elle une option ?\nQuels sont les effets secondaires des médicaments ?\nY a-t-il des thérapies complémentaires ?\nComment gérer les symptômes non moteurs ?", "url": "https://questionsmedicales.fr/mesh/D020734?mesh_terms=Double-Blind+Method&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndromes parkinsoniens", "description": "Quelles sont les complications courantes ?\nComment les chutes affectent-elles les patients ?\nLes troubles cognitifs sont-ils fréquents ?\nQuelles sont les complications psychologiques ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D020734?mesh_terms=Double-Blind+Method&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndromes parkinsoniens", "description": "Quels sont les principaux facteurs de risque ?\nLe sexe influence-t-il le risque ?\nLes traumatismes crâniens sont-ils un facteur ?\nL'exposition professionnelle joue-t-elle un rôle ?\nY a-t-il des liens avec d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D020734?mesh_terms=Double-Blind+Method&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un syndrome parkinsonien ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes moteurs et non moteurs." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie comme l'IRM et des évaluations neuropsychologiques peuvent être réalisés." } }, { "@type": "Question", "name": "Quels sont les critères de diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la bradykinésie, la rigidité et les tremblements au repos." } }, { "@type": "Question", "name": "Peut-on confondre avec d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme la maladie de Wilson ou des syndromes atypiques peuvent être confondues." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à identifier des facteurs de risque et des symptômes précurseurs." } }, { "@type": "Question", "name": "Quels sont les symptômes moteurs principaux ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes moteurs incluent la bradykinésie, la rigidité, et les tremblements." } }, { "@type": "Question", "name": "Quels symptômes non moteurs sont fréquents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes non moteurs incluent la dépression, l'anxiété et les troubles du sommeil." } }, { "@type": "Question", "name": "Comment évoluent les symptômes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes évoluent progressivement, souvent en s'aggravant avec le temps." } }, { "@type": "Question", "name": "Y a-t-il des symptômes précoces ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme la perte de l'odorat ou des troubles du sommeil peuvent apparaître tôt." } }, { "@type": "Question", "name": "Les symptômes affectent-ils la qualité de vie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent considérablement réduire la qualité de vie des patients." } }, { "@type": "Question", "name": "Peut-on prévenir les syndromes parkinsoniens ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention garantie, mais un mode de vie sain peut aider." } }, { "@type": "Question", "name": "Quel rôle joue l'exercice physique ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier peut améliorer la santé neurologique et retarder l'apparition des symptômes." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut réduire le risque de développer la maladie." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains pesticides et toxines peut augmenter le risque de Parkinson." } }, { "@type": "Question", "name": "Le stress a-t-il un impact ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut aggraver les symptômes et influencer la progression de la maladie." } }, { "@type": "Question", "name": "Quels sont les traitements médicamenteux ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la lévodopa, les agonistes de la dopamine et les inhibiteurs de la COMT." } }, { "@type": "Question", "name": "La chirurgie est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la stimulation cérébrale profonde peut être envisagée pour certains patients." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des nausées, des vertiges et des mouvements involontaires." } }, { "@type": "Question", "name": "Y a-t-il des thérapies complémentaires ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie et l'ergothérapie peuvent aider à améliorer la fonction motrice." } }, { "@type": "Question", "name": "Comment gérer les symptômes non moteurs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements psychologiques et des médicaments peuvent aider à gérer les symptômes non moteurs." } }, { "@type": "Question", "name": "Quelles sont les complications courantes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent les chutes, les troubles de la déglutition et les infections." } }, { "@type": "Question", "name": "Comment les chutes affectent-elles les patients ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les chutes peuvent entraîner des blessures graves, comme des fractures, et réduire l'autonomie." } }, { "@type": "Question", "name": "Les troubles cognitifs sont-ils fréquents ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreux patients développent des troubles cognitifs ou démence au cours de la maladie." } }, { "@type": "Question", "name": "Quelles sont les complications psychologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les patients peuvent souffrir de dépression, d'anxiété et d'isolement social." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une approche multidisciplinaire est essentielle pour gérer les complications efficacement." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge avancé, les antécédents familiaux et l'exposition à des toxines." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les hommes sont généralement plus susceptibles de développer des syndromes parkinsoniens." } }, { "@type": "Question", "name": "Les traumatismes crâniens sont-ils un facteur ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traumatismes crâniens répétés peuvent augmenter le risque de développer la maladie." } }, { "@type": "Question", "name": "L'exposition professionnelle joue-t-elle un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines professions exposant à des produits chimiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Y a-t-il des liens avec d'autres maladies ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies auto-immunes et métaboliques peuvent être associées à un risque accru." } } ] } ] }

Sources (10000 au total)

Evaluating the effectiveness of stromal-vascular fraction (SVF) cells along with subcision method in the treatment of acne scars: A double-blind randomized controlled clinical trial study.

Subcision method is one of the main techniques for treatment of acne scars or stromal-vascular fraction (SVF) and combined therapy can improve treatment strategy.... To use subcision method along with SVF for treatment of acne scar and comprised with alone subcision method.... In this double-blind clinical trial study, 10 patients with acne scars were entered into the study. Subcision technique was randomly performed on one side of the face and subcision technique plus SVF ... In terms of volume and area of scars, the mean percent change was 46.55 ± 13.92 and 44.60 ± 5.76, for the case group, and 13.31 ± 9.27 and 11.28 ± 9.64 for the control group, respectively. So, combine... According to the acquired results, combined therapy can be considered as effective and safe treatment for acne scars with significant higher efficacy compared with subcision alone....

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.

Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the on... ImmunoSep is a randomised placebo-controlled phase 2 clinical trial with a double-dummy design in which the effect of precision immunotherapy on sepsis phenotypes with MALS and immunoparalysis is stud... The protocol is approved by the German Federal Institute for Drugs and Medical Devices; the National Ethics Committee of Greece and by the National Organization for Medicines of Greece; the Central Co... NCT04990232....

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.

Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone p... In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), a... Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (... In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in simi... National Institute of Allergy and Infectious Diseases....

Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.

This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile.... This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamin... The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214-1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479-13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p ... This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effec... www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023....

A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.

Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across... To investigate the safety and tolerability of high-dose UDCA in PD and determine midbrain target engagement.... The UP (UDCA in PD) study was a phase II, randomized, double-blind, placebo-controlled trial of UDCA (30 mg/kg daily, 2:1 randomization UDCA vs. placebo) in 30 participants with PD for 48 weeks. The p... UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain... High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wile...

Intravenous vitamin C for vasoplegia: A double-blinded randomised clinical trial (VALENCIA trial).

To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock.... Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemi... Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ... In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors.... Prospective registration - trial number ACTRN12617001392358....

Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety.

Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such... We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone ... After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference -0.76%, 95% CI -6.34 to 4.82). ... The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP.... NCT02958917....

Comparison of intravenous ibuprofen and tenoxicam efficiency in ankle injury: a randomized, double-blind study.

Pain after soft tissue injuries in and around the ankle is a troublesome process in terms of patient comfort and mobilization. The aim of this study was to compare the analgesic efficacy of intravenou... We conducted a prospective, double-blind, randomized controlled study in a tertiary hospital. The patients were divided into two groups as those administered IV 400 mg ibuprofen and IV 20 mg tenoxicam... One hundred and twenty-four patients were included in the study. There were 62 patients in the tenoxicam group and 62 patients in the ibuprofen group. When VAS scores were compared, it was found that ...